Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022295 · ClinicalTrials.gov registry record · Phase 1
Phenoxodiol in Treating Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by Kazia Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00022295: Completed Phase 1 study, sponsored by Kazia Therapeutics Limited.
NCT00022295 is a Phase 1 study that has completed, run by Kazia Therapeutics Limited. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022295, a Phase 1 study, has completed, sponsored by Kazia Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.
Interventions
- DRUG idronoxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2001-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
What the finished NCT00022295 record still lists
NCT00022295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 1 intervention - of which idronoxil is the first listed.
NCT00022295 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00022295 about?
NCT00022295 is a clinical study titled "Phenoxodiol in Treating Patients With Refractory Solid Tumors". RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.
What is the current status of trial NCT00022295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2001-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00022295?
The interventions under investigation include: idronoxil (DRUG).
Who is sponsoring clinical trial NCT00022295?
This trial is sponsored by Kazia Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00022295's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia